Compare PED & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | ORMP |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 165.3M |
| IPO Year | 2012 | 2010 |
| Metric | PED | ORMP |
|---|---|---|
| Price | $12.49 | $4.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 63.5K | ★ 470.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $45,751,000.00 | $2,000,000.00 |
| Revenue This Year | $171.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.05 |
| Revenue Growth | 15.67 | ★ 49.25 |
| 52 Week Low | $0.43 | $1.98 |
| 52 Week High | $18.89 | $5.19 |
| Indicator | PED | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 60.43 |
| Support Level | $11.37 | $3.69 |
| Resistance Level | $14.20 | $5.10 |
| Average True Range (ATR) | 1.25 | 0.32 |
| MACD | 0.12 | 0.08 |
| Stochastic Oscillator | 21.44 | 58.74 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.